142 related articles for article (PubMed ID: 37357301)
61. Cholinesterase Inhibitors May Not Benefit Mild Cognitive Impairment and Mild Alzheimer Disease Dementia.
Han JY; Besser LM; Xiong C; Kukull WA; Morris JC
Alzheimer Dis Assoc Disord; 2019; 33(2):87-94. PubMed ID: 30633043
[TBL] [Abstract][Full Text] [Related]
62. Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer's Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression.
Tolar M; Hey J; Power A; Abushakra S
Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34198582
[TBL] [Abstract][Full Text] [Related]
63. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.
Sevigny JJ; Ryan JM; van Dyck CH; Peng Y; Lines CR; Nessly ML;
Neurology; 2008 Nov; 71(21):1702-8. PubMed ID: 19015485
[TBL] [Abstract][Full Text] [Related]
64. Identification of prognostic factors to predict cognitive decline of patients with early Alzheimer's disease in the Japanese Alzheimer's Disease Neuroimaging Initiative study.
Yagi T; Kanekiyo M; Ito J; Ihara R; Suzuki K; Iwata A; Iwatsubo T; Aoshima K; ;
Alzheimers Dement (N Y); 2019; 5():364-373. PubMed ID: 31440579
[TBL] [Abstract][Full Text] [Related]
65. Economic evaluation of supplementing the diet with Souvenaid in patients with prodromal Alzheimer's disease.
Mar J; Gorostiza A; Ibarrondo O; Larrañaga I; Arrospide A; Martinez-Lage P; Soto-Gordoa M
Alzheimers Res Ther; 2020 Dec; 12(1):166. PubMed ID: 33308302
[TBL] [Abstract][Full Text] [Related]
66. Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients.
Siemers ER; Sundell KL; Carlson C; Case M; Sethuraman G; Liu-Seifert H; Dowsett SA; Pontecorvo MJ; Dean RA; Demattos R
Alzheimers Dement; 2016 Feb; 12(2):110-120. PubMed ID: 26238576
[TBL] [Abstract][Full Text] [Related]
67. Utilization of Observational Data as a Proxy Cohort for Comparison Purposes with Open-Label Study Results: An Example from Alzheimer's Disease.
Reed C; Happich M; Raskin J; Tockhorn-Heidenreich A; Belger M
J Prev Alzheimers Dis; 2019; 6(2):90-99. PubMed ID: 30756115
[TBL] [Abstract][Full Text] [Related]
68. Progression of Alzheimer's Disease: A Longitudinal Study in Norwegian Memory Clinics.
Eldholm RS; Barca ML; Persson K; Knapskog AB; Kersten H; Engedal K; Selbæk G; Brækhus A; Skovlund E; Saltvedt I
J Alzheimers Dis; 2018; 61(3):1221-1232. PubMed ID: 29254085
[TBL] [Abstract][Full Text] [Related]
69. A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: the DARAD trial.
Molloy DW; Standish TI; Zhou Q; Guyatt G;
Int J Geriatr Psychiatry; 2013 May; 28(5):463-70. PubMed ID: 22718435
[TBL] [Abstract][Full Text] [Related]
70. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
Aisen PS; Schafer KA; Grundman M; Pfeiffer E; Sano M; Davis KL; Farlow MR; Jin S; Thomas RG; Thal LJ;
JAMA; 2003 Jun; 289(21):2819-26. PubMed ID: 12783912
[TBL] [Abstract][Full Text] [Related]
71. The effects of donepezil in Alzheimer's disease - results from a multinational trial.
Burns A; Rossor M; Hecker J; Gauthier S; Petit H; Möller HJ; Rogers SL; Friedhoff LT
Dement Geriatr Cogn Disord; 1999; 10(3):237-44. PubMed ID: 10325453
[TBL] [Abstract][Full Text] [Related]
72. Omega-3 fatty acids for the treatment of dementia.
Burckhardt M; Herke M; Wustmann T; Watzke S; Langer G; Fink A
Cochrane Database Syst Rev; 2016 Apr; 4(4):CD009002. PubMed ID: 27063583
[TBL] [Abstract][Full Text] [Related]
73. Cognitive and functional progression in Alzheimer disease: A prediction model of latent classes.
Haaksma ML; Calderón-Larrañaga A; Olde Rikkert MGM; Melis RJF; Leoutsakos JS
Int J Geriatr Psychiatry; 2018 Aug; 33(8):1057-1064. PubMed ID: 29761569
[TBL] [Abstract][Full Text] [Related]
74. Effect of Vascular Risk Factors on the Progression of Mild Alzheimer's Disease and Lewy Body Dementia.
Bergland AK; Dalen I; Larsen AI; Aarsland D; Soennesyn H
J Alzheimers Dis; 2017; 56(2):575-584. PubMed ID: 28035932
[TBL] [Abstract][Full Text] [Related]
75. Differences in Alzheimer disease clinical trial outcomes based on age of the participants.
Schneider LS; Kennedy RE; Wang G; Cutter GR
Neurology; 2015 Mar; 84(11):1121-7. PubMed ID: 25681452
[TBL] [Abstract][Full Text] [Related]
76. Development of a straightforward and sensitive scale for MCI and early AD clinical trials.
Huang Y; Ito K; Billing CB; Anziano RJ;
Alzheimers Dement; 2015 Apr; 11(4):404-14. PubMed ID: 25022537
[TBL] [Abstract][Full Text] [Related]
77. Is Ongoing Anticholinergic Burden Associated With Greater Cognitive Decline and Dementia Severity in Mild to Moderate Alzheimer's Disease?
Dyer AH; Murphy C; Segurado R; Lawlor B; Kennelly SP;
J Gerontol A Biol Sci Med Sci; 2020 Apr; 75(5):987-994. PubMed ID: 31613323
[TBL] [Abstract][Full Text] [Related]
78. Rationale for use of the Clinical Dementia Rating Sum of Boxes as a primary outcome measure for Alzheimer's disease clinical trials.
Cedarbaum JM; Jaros M; Hernandez C; Coley N; Andrieu S; Grundman M; Vellas B;
Alzheimers Dement; 2013 Feb; 9(1 Suppl):S45-55. PubMed ID: 22658286
[TBL] [Abstract][Full Text] [Related]
79. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial.
Akhondzadeh S; Noroozian M; Mohammadi M; Ohadinia S; Jamshidi AH; Khani M
J Clin Pharm Ther; 2003 Feb; 28(1):53-9. PubMed ID: 12605619
[TBL] [Abstract][Full Text] [Related]
80. Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.
Tolar M; Abushakra S; Hey JA; Porsteinsson A; Sabbagh M
Alzheimers Res Ther; 2020 Aug; 12(1):95. PubMed ID: 32787971
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
